Richard Buus

1.8k total citations
33 papers, 930 citations indexed

About

Richard Buus is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, Richard Buus has authored 33 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cancer Research, 17 papers in Oncology and 11 papers in Genetics. Recurrent topics in Richard Buus's work include Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (8 papers). Richard Buus is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (8 papers). Richard Buus collaborates with scholars based in United Kingdom, Germany and United States. Richard Buus's co-authors include Mitch Dowsett, Ivana Šestak, Jack Cuzick, Ralf Kronenwett, Peter Dubsky, Carsten Denkert, Sean Ferree, Catherine A. Schnabel, Frederick L. Baehner and Marco Falasca and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Richard Buus

32 papers receiving 916 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Buus United Kingdom 14 565 477 369 229 193 33 930
Femke A. de Snoo Netherlands 17 546 1.0× 556 1.2× 284 0.8× 102 0.4× 178 0.9× 27 870
Shannon L. Puhalla United States 15 477 0.8× 635 1.3× 319 0.9× 285 1.2× 231 1.2× 44 995
Aiko Sueta Japan 18 487 0.9× 340 0.7× 455 1.2× 185 0.8× 157 0.8× 45 947
Rosalía Caballero Spain 14 599 1.1× 639 1.3× 454 1.2× 157 0.7× 178 0.9× 42 1.2k
Jarle B. Arnes Norway 18 418 0.7× 431 0.9× 567 1.5× 125 0.5× 106 0.5× 28 1.0k
Lennart Mulder Netherlands 14 438 0.8× 442 0.9× 393 1.1× 119 0.5× 250 1.3× 25 829
Ahmed Benhasouna United Kingdom 9 452 0.8× 543 1.1× 428 1.2× 139 0.6× 90 0.5× 10 937
Kimberly B. Koenig United States 12 475 0.8× 510 1.1× 245 0.7× 203 0.9× 160 0.8× 15 855
Stephan Duss Switzerland 12 520 0.9× 682 1.4× 669 1.8× 196 0.9× 226 1.2× 13 1.3k
Anita Bane Canada 19 509 0.9× 543 1.1× 440 1.2× 151 0.7× 129 0.7× 41 1.2k

Countries citing papers authored by Richard Buus

Since Specialization
Citations

This map shows the geographic impact of Richard Buus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Buus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Buus more than expected).

Fields of papers citing papers by Richard Buus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Buus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Buus. The network helps show where Richard Buus may publish in the future.

Co-authorship network of co-authors of Richard Buus

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Buus. A scholar is included among the top collaborators of Richard Buus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Buus. Richard Buus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pece, Salvatore, Ivana Šestak, Francesca Montani, et al.. (2022). Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. European Journal of Cancer. 164. 52–61. 6 indexed citations
2.
Buus, Richard, Zsolt Szíjgyártó, Eugene F. Schuster, et al.. (2021). Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. npj Breast Cancer. 7(1). 15–15. 9 indexed citations
3.
Buus, Richard, et al.. (2021). Development and validation of an open-source method for research assessment of Oncotype DX Breast Recurrence Score, EndoPredict and Prosigna. 1 indexed citations
4.
Bergerhoff, Katharina, Shane Foo, Emmanuel C. Patin, et al.. (2020). Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Journal for ImmunoTherapy of Cancer. 8(2). e000698–e000698. 24 indexed citations
5.
Buus, Richard, Ivana Šestak, Ralf Kronenwett, et al.. (2020). Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. Journal of Clinical Oncology. 39(2). 126–135. 62 indexed citations
6.
Leal, Mariana Ferreira, Ben P. Haynes, Eugene F. Schuster, et al.. (2019). Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. Clinical Cancer Research. 25(24). 7485–7496. 13 indexed citations
7.
Šestak, Ivana, Miguel Martín, Peter Dubsky, et al.. (2019). Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment. 176(2). 377–386. 57 indexed citations
8.
Buus, Richard, Ivana Šestak, Stephen Barron, et al.. (2019). Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study. Clinical Cancer Research. 26(3). 623–631. 8 indexed citations
9.
Šestak, Ivana, Richard Buus, Jack Cuzick, et al.. (2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology. 4(4). 545–545. 204 indexed citations
10.
López‐Knowles, Elena, Alex Pearson, Eugene F. Schuster, et al.. (2018). Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. British Journal of Cancer. 120(2). 247–255. 12 indexed citations
11.
Buus, Richard, Belinda Yeo, Adam R. Brentnall, et al.. (2018). Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. Breast Cancer Research. 20(1). 103–103. 7 indexed citations
12.
Lawler, Katherine, Efterpi Papouli, Cristina Naceur‐Lombardelli, et al.. (2017). Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast Cancer Research. 19(1). 113–113. 4 indexed citations
13.
Huang, Paul H., Frank McCarthy, Khin Thway, et al.. (2017). A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma. Annals of Oncology. 28. x149–x149. 2 indexed citations
14.
Buus, Richard, Ivana Šestak, Ralf Kronenwett, et al.. (2016). Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. JNCI Journal of the National Cancer Institute. 108(11). djw149–djw149. 152 indexed citations
15.
Klintman, Marie, Richard Buus, Maggie C.U. Cheang, et al.. (2016). Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. Clinical Cancer Research. 22(10). 2405–2416. 38 indexed citations
16.
Buus, Richard, Marie Klintman, Amna Sheri, Maggie C.U. Cheang, & Mitch Dowsett. (2015). Abstract 5294: Biomarkers in residual disease after neoadjuvant chemotherapy of breast cancer predict long-term outcome. Cancer Research. 75(15_Supplement). 5294–5294. 1 indexed citations
17.
Dowsett, Mitch, Ivana Šestak, Richard Buus, et al.. (2015). Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clinical Cancer Research. 21(12). 2763–2770. 33 indexed citations
18.
Edling, Charlotte E., Federico Selvaggi, Richard Buus, et al.. (2010). Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer. Clinical Cancer Research. 16(20). 4928–4937. 80 indexed citations
19.
Buus, Richard, Monica Faronato, Dean E. Hammond, Sylvie Urbé, & Michael J. Clague. (2009). Deubiquitinase Activities Required for Hepatocyte Growth Factor-Induced Scattering of Epithelial Cells. Current Biology. 19(17). 1463–1466. 48 indexed citations
20.
Liu, Han, Richard Buus, Michael J. Clague, & Sylvie Urbé. (2009). Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1. PLoS ONE. 4(5). e5544–e5544. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Femke A. de Snoo Breakdown of academic impact, for papers by Shannon L. Puhalla Breakdown of academic impact, for papers by Aiko Sueta Breakdown of academic impact, for papers by Rosalía Caballero Breakdown of academic impact, for papers by Jarle B. Arnes Breakdown of academic impact, for papers by Lennart Mulder Breakdown of academic impact, for papers by Ahmed Benhasouna Breakdown of academic impact, for papers by Kimberly B. Koenig Breakdown of academic impact, for papers by Stephan Duss Breakdown of academic impact, for papers by Anita Bane
Rankless by CCL
2026